You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

176 Results
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Adjuvant, Palliative
Apr 2023
Regimen
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    letrozole
Oct 2025
Regimen
Intent: Adjuvant, Palliative
Funding:
Exceptional Access Program
    abemaciclib - For the adjuvant treatment, in combination with endocrine therapy, of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence, according to criteria
ODB - General Benefit
    anastrozole
Oct 2025
Regimen
Cancer Type:
Sarcoma, 
Ewing's, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
Feb 2018
Regimen
Intent: Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Jan 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
  • goserelin
Mar 2016
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Neoadjuvant, Adjuvant, Palliative
Funding:
ODB - General Benefit
    leuprolide - long-acting formulation
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Adjuvant
Nov 2022
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Adjuvant
Apr 2023
Regimen
Intent: Neoadjuvant, Adjuvant
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Adjuvant Treatment for Breast Cancer
Feb 2022
Regimen

Pages